These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9186684)

  • 41. CD40 signaling replaces CD4+ lymphocytes and its blocking prevents chronic rejection of heart transplants.
    Fischbein MP; Ardehali A; Yun J; Schoenberger S; Laks H; Irie Y; Dempsey P; Cheng G; Fishbein MC; Bonavida B
    J Immunol; 2000 Dec; 165(12):7316-22. PubMed ID: 11120867
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CD40-CD40L interactions provide "third-party" costimulation for T cell response against B7-1-transfected human breast tumor cells.
    Pericle F; Epling-Burnette PK; Podack ER; Wei S; Djeu JY
    J Leukoc Biol; 1997 Feb; 61(2):201-8. PubMed ID: 9021926
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The CD40-CD154 system in anti-infective host defense.
    Grewal IS; Borrow P; Pamer EG; Oldstone MB; Flavell RA
    Curr Opin Immunol; 1997 Aug; 9(4):491-7. PubMed ID: 9287184
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CD40-CD40 ligand.
    van Kooten C; Banchereau J
    J Leukoc Biol; 2000 Jan; 67(1):2-17. PubMed ID: 10647992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regulation of cytoplasmic, surface and soluble forms of CD40 ligand in mouse B cells.
    Wykes M; Poudrier J; Lindstedt R; Gray D
    Eur J Immunol; 1998 Feb; 28(2):548-59. PubMed ID: 9521065
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD40 and autoimmunity: the dark side of a great activator.
    Peters AL; Stunz LL; Bishop GA
    Semin Immunol; 2009 Oct; 21(5):293-300. PubMed ID: 19595612
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of CD40 in the regulation of humoral and cell-mediated immunity.
    Durie FH; Foy TM; Masters SR; Laman JD; Noelle RJ
    Immunol Today; 1994 Sep; 15(9):406-11. PubMed ID: 7524518
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD40 and its ligand in the regulation of humoral immunity.
    Klaus SJ; Berberich I; Shu G; Clark EA
    Semin Immunol; 1994 Oct; 6(5):279-86. PubMed ID: 7532458
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis.
    Ohata J; Sakurai J; Saito K; Tani K; Asano S; Azuma M
    Clin Exp Immunol; 2002 Jul; 129(1):61-8. PubMed ID: 12100023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. B cells can prime naive CD4+ T cells in vivo in the absence of other professional antigen-presenting cells in a CD154-CD40-dependent manner.
    Rodríguez-Pinto D; Moreno J
    Eur J Immunol; 2005 Apr; 35(4):1097-105. PubMed ID: 15756646
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
    Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
    J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activated T hybridomas induce upregulation of B7-1 on bystander B lymphoma cells by a contact-dependent interaction utilizing CD40 ligand.
    Jones KW; Hackett CJ
    Cell Immunol; 1996 Nov; 174(1):42-53. PubMed ID: 8929453
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nucleosome-driven autoimmune response in lupus. Pathogenic T helper cell epitopes and costimulatory signals.
    Datta SK; Kaliyaperumal A
    Ann N Y Acad Sci; 1997 Apr; 815():155-70. PubMed ID: 9186652
    [No Abstract]   [Full Text] [Related]  

  • 54. Polyphenolic antioxidants inhibit peptide presentation by antigen-presenting cells.
    Gong J; Chen SS
    Int Immunopharmacol; 2003 Dec; 3(13-14):1841-52. PubMed ID: 14636833
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activation of bovine B cells via surface immunoglobulin M cross-linking or CD40 ligation results in different B-cell phenotypes.
    Haas KM; Estes DM
    Immunology; 2000 Feb; 99(2):272-8. PubMed ID: 10692047
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD4+ T lymphocytes expressing CD40 ligand help the IgM antibody response to soluble pneumococcal polysaccharides via an intermediate cell type.
    Jeurissen A; Billiau AD; Moens L; Shengqiao L; Landuyt W; Wuyts G; Boon L; Waer M; Ceuppens JL; Bossuyt X
    J Immunol; 2006 Jan; 176(1):529-36. PubMed ID: 16365447
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Induction of dendritic cell costimulator molecule expression is suppressed by T cells in the absence of antigen-specific signalling: role of cluster formation, CD40 and HLA-class II for dendritic cell activation.
    McLellan AD; Heiser A; Hart DN
    Immunology; 1999 Oct; 98(2):171-80. PubMed ID: 10540215
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interaction of B cells with activated T cells reduces the threshold for CD40-mediated B cell activation.
    Klaus GG; Holman M; Johnson-Léger C; Christenson JR; Kehry MR
    Int Immunol; 1999 Jan; 11(1):71-9. PubMed ID: 10050675
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic potential for blockade of the CD40 ligand, gp39.
    Buhlmann JE; Noelle RJ
    J Clin Immunol; 1996 Mar; 16(2):83-9. PubMed ID: 8690776
    [No Abstract]   [Full Text] [Related]  

  • 60. Effects of CD40 stimulation in the prevention of human EBV-lymphomagenesis.
    Funakoshi S; Taub DD; Asai O; Hirano A; Ruscetti FW; Longo DL; Murphy WJ
    Leuk Lymphoma; 1997 Jan; 24(3-4):187-99. PubMed ID: 9156649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.